new version available

Newsletter Sign Up

Please enter your email to receive FREE venture capital and private equity special offers, news, and information!

Your Name: 

Your Email:  

bookmark us

02/07/2007

Genizon Secures $8.5 Million in Series D Financing

 

Genizon BioSciences recently announced the first closing of its Series D equity financing, in the amount of $8.5 million. Investors include Pfizer Inc. and existing investor BTF B.V. of Haarlem, The Netherlands, a venture capital fund focused on late stage biotechnology companies. Pfizer's investment in Genizon is related to a license and collaboration agreement announced last month.

Genizon will use the funds to conduct genome-wide association studies in the Quebec Founder Population and to enhance and commercialize discoveries already generated from previous studies. 

“Genizon is poised to capitalize on its lead in genome-wide scanning and disease gene discovery, and this will be enabled by this financing,” said John Hooper, Ph.D., President and CEO of Genizon. “Pfizer represents a significant new investor for Genizon, particularly given Pfizer's collaboration in three of Genizon's programs. We are also pleased by the additional investment from BTF, which will be pivotal in adding value.”

“We are excited about Genizon's development over the last year,” stated Jan Mellegers, CEO of BTF. “This additional investment in the company reinforces our belief in the value being generated by Genizon's gene discovery programs and through its alliances.”

Genizon conducts genome-wide association studies involving more than 40,000 members of the Quebec Founder Population, whose extensive genetic sharing and low genetic variability are ideally suited for the discovery of genes affecting people worldwide in the many common diseases with strong genetic components. Genizon has completed eight genome-wide association studies to date, with several more planned for 2007.

Genizon BioSciences Inc., founded in 1999, is the only source for GeneMaps-comprehensive maps of genes, genetic markers, biochemical pathways and drug targets that are unequivocally involved in causing human disease-accelerating the development of safer, more effective medicines. GeneMaps also lead to the development of predictive diagnostics that facilitate personalized medicine. Genizon's proprietary, automated gene discovery platform using genome-wide association studies involving thousands of members of the Quebec Founder Population provides unprecedented understanding of the genetic origins and mechanisms of common diseases, resulting in the best possible drug targets and genetic markers. The company's GeneMaps provide pharmaceutical partners with intellectual property that creates opportunities for leadership in many therapeutic areas by bringing to market better treatments that address the root causes of diseases. Genizon is conducting gene discovery programs in more than 25 common diseases. Genizon also provides high throughput, high quality SNP genotyping, genetic analysis, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry.

For more information, please visit: www.genizon.com/html/index.asp